Detail akcie Sarepta online

Business Summary: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Sarepta Therapeutics Inc revenues increased 75% to $1.36B. Net loss totaled $250.6M vs. income of $42.6M. Revenues reflect ELEVIDYS segment increase from $255.7M to $656.8M, VYONDYS 53 segment increase from $56.4M to $231.3M. Net loss reflects Research and development- other increase from $265.1M to $854.4M (expense), Accretion of investment discount decrease of 82% to $4.1M (income).